Disclosure Statement

A Joint Working Project between Bristol-Myers Squibb Pharmaceuticals Limited (BMS) on its own behalf and for the benefit of Pfizer Limited (the **Alliance Partner) and Staffordshire Sustainability and Transformation Partnership (STP)**

Name of Project:	**Implementation of Staffordshire-wide Technology Enabled Care Services (TECS) and a North Staffordshire Division Service Improvement Pilot**

Project Overview:	This is a Joint Working Project between Bristol-Myers Squibb Pharmaceuticals Limited (BMS) and Staffordshire STP. This documentation is produced by BMS.
	
	The joint working project will focus on delivering two key initiatives;
	
	    ▪ **Implementation of Technology Enabled Care Services to support improvements in the management and outcomes for patients with atrial fibrillation (AF) and hypertension.**
	    ▪ **A pilot service improvement project to Increase the capability and capacity within to better "protect" and "perfect" patients with AF.**
	
	The primary aim of the project is to prevent AF related strokes through implementation of Technology Enabled Care Services, in conjunction with running the service improvement pilot in the Northern Staffordshire Division.
	
	The project will support the Staffordshire-wide implementation of technology-enabled care services initiative, aligned to the National Health Service England (NHSE)/Public Health England (PHE) *"The Size of the Prize in Cardiovascular Disease Prevention"*.[1] the AHSN Network – *"National programmes and priorities"*.[2], where Atrial Fibrillation (AF) is one of the seven programmes selected for national adoption and the *AF Toolkit – Detect, Protect and Perfect – Working together across London to prevent AF related Strokes*.[3] In conjunction with this, a service improvement pilot will be implemented. The pilot will be designed to increase the capability and capacity to better "perfect" patients with Atrial Fibrillation (AF) within the North Staffordshire Division (North Staffordshire CCG and Stoke-on-Trent CCG). The joint working project will focus on supporting the "protect" and "perfect" aspects of the AHSN Network national programme, AF workstream and will align with the definitions set out in the AF Toolkit – Detect, Protect and Perfect – working together across London to prevent AF related strokes.[4]

Project Objectives:	The key objectives comprise;
	
	    ▪ Improving care and outcomes and reduce unwarranted variation for local AF patients
	    ▪ Achieving clinical and digital upskilling around deployment of technology-enabled care services across the AF pathway
	    ▪ Impacting on local "protect" and "perfect" gaps as defined in the pan-London Toolkit[5]
	    ▪ Increasing GP education, clinical confidence and capacity for delivery of technology enabled care services for their local AF patients
	    ▪ Empowering patients/people to take personal responsibility for their care in relation to AF, hypertension and adverse lifestyle habits, patient activation and management

[1] The Size of the Prize in Cardiovascular Disease (CVD) Prevention, Staffordshire. Public Health England, NHS England. [downloaded 7.02.18]

[2] Academic Health Science Network (AHSN) National Programmes: Atrial Fibrillation: detect, protect and perfect. Link: https://www.ahsnnetwork.com/about-academic-health-science-networks/national-programmes-priorities/atrial-fibrillation/ [Accessed online 14.2.2019]

[3] Atrial Fibrillation Toolkit. Detect, Protect, Correct and Perfect – Working together across London to prevent AF related strokes. *www.londonscn.nhs.uk* [accessed online 14.2.2019]

[4] Atrial Fibrillation Toolkit. Detect, Protect, Correct and Perfect – Working together across London to prevent AF related strokes. *www.londonscn.nhs.uk* [accessed online 14.2.2019]

[5] Atrial Fibrillation Toolkit. Detect, Protect, Correct and Perfect – Working together across London to prevent AF related strokes. *www.londonscn.nhs.uk* [accessed online 14.2.2019]

Patient Benefits:	- Patients will benefit from more strategic and rapid implementation of relevant national guidance, informing a population-wide reduction in the risk of stroke. This will mean more AF & hypertensive patients detected and treated appropriately and engaged with services. This in turn will support a future reduction in the risk of stroke and enhance protection from harm. - More patients will be appropriately risk-assessed and adequately anti-coagulated, helping to mitigate for future AF stroke aversion. - Patients will be empowered to take more responsibility for their health. This in turn, will contribute to better medicines adherence and medicines compliance, meaning their condition (AF and/or hypertension and pre-vascular dementia) will be more effectively managed. This will also build lay patient scientific and medicines literacy, helping the patients feel more in control and involved in their care, ultimately, helping to build better social capital across the locality and support achievement of 'The Size of the Prize in cardiovascular disease prevention'- saving lives and reducing ill-health. - Improving patient adherence will impact across; safety, outcomes, cost-effectiveness, quality of life and preventative strategy modelling, all in line with relevant NHSE/PHE agendas. - Helping to address the unmet need and focus on the AF and hypertensive populations, in line with the national imperative of "The Size of the Prize in cardiovascular disease prevention" and the "Detect, Protect, Perfect" agenda, will help reach more of the local vulnerable population and strengthen any subsequent impact on reducing health inequalities and the health and social care bill duties that relate to this.
Stakeholders	- Staffordshire Sustainability and Transformation Partnership (STP) - Bristol-Myers Squibb Pharmaceuticals Limited (BMS), who is entering into the agreement on its own behalf and for the benefit of Pfizer Limited (the **Alliance Partner**)
Timelines:	The project will begin from March 2019 and last for a 9 month period to the end of 2019